Abstract
Tyrosine kinase inhibitors (TKIs) of the anaplastic lymphoma kinase gene (ALK) significantly improve quality of life and survival in non-small cell lung cancer (NSCLC) with ALK fusion. However, ALK fusion is extremely rare in small-cell lung cancer (SCLC), and there is no standard treatment at present, and the mechanism of resistance of ALK-TKIs in SCLC is unknown.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
